Compare Newmont Corporation (NEM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Sana Biotechnology Inc — how do they compare? Newmont Corporation trades at $128.7 (market cap $133.91B), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: Newmont Corporation is far larger — about 130× Sana Biotechnology Inc's market cap, and Newmont Corporation pays a 0.82% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NEM | SANA | |
|---|---|---|
Market Cap | $133.91B | $1.03B |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $5.92 |
52-Week Low | $78.32 | $2.68 |
Enterprise Value | $130.50B | $946.04M |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $127.09, down 0.78% on the day, with strong fundamental performance including a 31.25% net income margin in 2025 and consistent earnings beats. The stock shows bullish technical signals with moving averages supporting upside, while recent news highlights production challenges and institutional accumulation. Revenue growth is robust, projected to reach $25.8 billion in 2026.
Outlook remains positive due to high analyst buy ratings (75.68%) and a $133.29 consensus price target, though risks include operational pressures and gold price volatility. The company's liquidity and debt reduction support shareholder returns, including dividends.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
